[Comparative Clinical Biochemical Assessment of the State of Myocardium After Coronary Artery Bypass Surgery Performed Using Various Techniques].

We compared parameters of the state of myocardium after coronary artery bypass surgery (CABS) performed according to the following techniques - with complete cardiopulmonary bypass (CABS-CBP), beating heart bypass grafting with parallel normothermic perfusion (CABS-BH-NP), and beating heart bypass grafting (CABS-BH). Patients (n=100, 86% men, 14% women, age 56-69 years) were divided into 3 groups with comparable sex, age, state of the myocardium, and EUROSCORE surgical risk. In group 1 patients (n=35) we used CABS-CHB, in group 2 (n=32) - CABS-BH-NP, in group 3 (n=33) - CABS-BH.

[Comparative Clinical Biochemical Assesment of the State of Mycardium After Coronary Artery Bypass Surgery Performed Using Various Techniques].

We compared parameters of the state of myocardium after coronary artery bypass surgery (CABS) performed according to the following techniques--with complete cardiopulmonary bypass (CABS-CBP), beating heart bypass grafting with parallel normothermic perfusion (CABS- BH-NP), and beating heart bypass grafting (CABS-BH). Patients (n = 100, 86% men, 14% women, age 56-69 years) were divided into 3 groups with comparable sex, age, state of the myocardium, and EUROSCORE surgical risk. In group 1 patients (n = 35) we used CABS-CHB, in group 2 (n = 32)--CABS-BH-NP, in group 3 (n = 33)--CABS-BH.

[Controlled release metoprolol succinate in MERIT-HF. Analysis of patients subgroups].

Results of the investigation of metoprolol CR/XL which was conducted in large randomized controlled study MERIT-HF in patients with chronic heart failure (CHF) are presented. In the whole trial this beta1-selective blocker lowered mortality of patients with CHF. Analysis of results in subgroups shows that metoprolol CR/XL was equally effective in middle aged and old patients, in men and women.

[Brain natriuretic peptide as marker and factor of prognosis in chronic heart failure].

The role of natriuretic peptides in pathogenesis of chronic heart failure (CHF) is reviewed. Main attention is given to significance of measurement of brain natriuretic peptide in the following clinical situations related to CHF: diagnosis of CHF, screening of patients with symptomless left ventricular dysfunction, differential diagnosis of edematous syndrome, indications to therapy and monitoring of its effectiveness, assessment of long term prognosis of patients with CHF. Possibilities of curative use of natriuretic peptides and inhibitors of vasopeptidases are also discussed.